Physician profile
William J Sarantos
NPI 1023192671
$1,159.37
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $271 · 2021: $248 · 2022: $295 · 2023: $44.95 · 2024: $46.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $391.30 | 2021-2023 | Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $172.97 | 2020-2022 | |
| Novo Nordisk INC | $117.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $102.69 | 2019-2022 | |
| Abbott Laboratories | $92.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $64.37 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $59.70 | 2020 | |
| Allergan, INC. | $56.45 | 2019-2020 | |
| Lilly USA, LLC | $30.40 | 2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $30.13 | 2021-2024 | Airsupra |
| Pfizer INC. | $15.98 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.21 | 2022 | |
| Genentech USA, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sarantos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.